COVID-19 vaccine developers drop out…GC Pharma remains

Four pre-clinical stage companies→single Phase 2 candidate firm…government funding centers only to GC Pharma

KRW 20B will be allocated until 2027…mRNA vaccine and platform are expected to be secured

The competitive landscape for COVID-19 vaccine development in South Korea currently centers on GC Pharma. While numerous biopharmaceutical firms began vaccine R&D during the pandemic, the transition to endemic status led to program terminations and corporate downsizings, leaving GC Pharma as the only remaining participant in the Phase 2 clinical stage of the government’s "mRNA Vaccine Development Project for Pandemic Preparedness."

GC Pharma recently submitted an amendment request for the Phase 2 clinical trial Investigational New Drug (IND) application for its COVID-19 mRNA vaccine candidate, 'GC4006A,' to the Ministry of Food and Drug Safety (MFDS). GC Pharma was previously designated as the sole company for the Phase 2 clinical research task under the government project jointly led by the Korea Disease Control and Prevention Agency (KDCA) and the Korea Health Industry Development Institute (KHIDI).

According to the KDCA, approximately KRW 20 billion (around $14.5 million) in government R&D funding will be allocated to GC Pharma’s Phase 2 trial from August 2026 through December 2027. GC Pharma aims to initiate the Phase 2 trial within the year, submit the Phase 3 IND next year, and secure final marketing authorization by 2028.

This study will evaluate the optimal dosage and immunogenicity of GC4006A in healthy adults and elderly individuals aged 19 to 85, comparing results against a control group. GC4006A is the first clinical-stage pipeline candidate developed using GC Pharma's proprietary mRNA-LNP platform.

GC Pharma Major R&D Pipelines: GC Pharma is pursuing marketing authorization for its Hunter syndrome therapy 'GC1123B'. It is also advancing global clinical trials for its Sanfilippo syndrome type A candidate ('GC1130A') and Fabry disease therapy ('GC1134A'). In vaccines, in addition to GC4006A, GC Pharma is developing a Tdap vaccine candidate ('GC3111B') and a two-dose varicella vaccine ('MG1111D'). MG1111D is undergoing Phase 3 clinical trials in Thailand and Vietnam, entering Phase 3 trial IND in South Korea.

From four non-clinical participating companies to a single Phase 2 candidate

Participating companies dwindled rapidly as government-funded projects advanced to higher clinical stages.

During the pandemic, domestic firms pursued diverse platforms, including DNA, recombinant protein, and viral vector vaccines. However, as commercial viability dwindled amid the shift to endemic conditions, most developers suspended or slowed their programs.

Consequently, the government-funded program downsized from four non-clinical contenders to a single Phase 2 candidate, leaving GC Pharma as the sole developer standing. If GC4006A achieves commercial approval, it will become South Korea’s second domestic COVID-19 vaccine and its first domestically developed mRNA vaccine.

Previously, SK bioscience secured authorization for South Korea’s first domestic COVID-19 vaccine, 'SKYCovione' (a recombinant protein vaccine), in June 2022. No additional domestic COVID-19 vaccines have been approved since.

Under this program, government regulatory support will continue throughout the authorization process. The KDCA plans to operate a regular consultative body with the MFDS to address regulatory issues during clinical development. However, this consultative effort is intended to facilitate administrative review and does not automatically guarantee expedited approval.

While some industry observers question the commercial rationale for developing a COVID-19 vaccine in the endemic era, both health authorities and industry experts prioritize securing the underlying mRNA platform rather than the COVID-19 candidate itself.

mRNA represents a next-generation platform technology that allows rapid candidate design following the identification of pathogen gene sequences during future outbreaks of emerging infectious diseases. The platform holds immense strategic value, as it can be deployed against future variants, avian influenza (AI), and novel respiratory pathogens.

A "Two-Track" strategy for new orphan drugs and vaccines...mRNA development expands vaccine competitiveness

For GC Pharma, the project means more than developing a COVID-19 product. The company is expanding its R&D under a two-track growth strategy encompassing both rare-disease therapeutics and preventive vaccines.

In rare diseases, GC Pharma is pursuing marketing authorization for its Hunter syndrome therapy 'GC1123B'. It is also advancing global clinical trials for its Sanfilippo syndrome type A candidate ('GC1130A') and Fabry disease therapy ('GC1134A'). In vaccines, in addition to GC4006A, GC Pharma is developing a Tdap vaccine candidate ('GC3111B') and a two-dose varicella vaccine ('MG1111D'). MG1111D is undergoing Phase 3 clinical trials in Thailand and Vietnam, with preparations underway to enter Phase 3 trials in South Korea.

If GC4006A successfully processes through commercial approval, GC Pharma will add a next-generation mRNA platform to its existing preventive vaccine portfolio. This addition is expected to advance its vaccine pipeline while significantly enhancing its competitiveness for future pandemic response.

An industry source said, "While the commercial market for COVID-19 vaccines has downsized significantly since the pandemic, the strategic value of the mRNA platform has only intensified," and added, "As one of the few domestic companies capable of developing both therapeutics and vaccines in-house, securing an mRNA vaccine platform will strengthen GC Pharma's dual-track R&D strategy."